Thymosin Alpha-1
Clinical evidence
Extensively studied (11,000+ subjects) with real, strong benefit in specific conditions like hepatitis B, while a large sepsis trial found no benefit. Evidence is condition-specific.
Studied in more than 11,000 human subjects across trials. Real, strong results exist and are specific to particular conditions: a pivotal RCT in chronic hepatitis B found 40.6% complete virological response with a 26-week course vs. 9.4% in controls; a 12-month trial in pulmonary tuberculosis patients with diabetes found significantly better sputum-clearance and lesion-resolution rates alongside increased CD3+/CD4+/NK-cell counts. Results vary by condition: a large Phase 3 sepsis trial (22 centers, China) found no significant benefit on any outcome. Mechanistically, it raises CD4+ T-cell levels and CD4/CD8 ratio, which is why it is studied in immunocompromised populations (HIV, cancer-related immunosuppression, age-related immune decline). Those trial populations are specific; a healthy adult is a different context.
Sources
LL-37 (Cathelicidin)
Clinical evidence
Real trial data exists, almost entirely for topical wound healing. The antimicrobial and immune mechanisms are well-studied in the lab, with human trials for those broader applications still early.
The most advanced human data is in topical wound healing: a Phase IIb RCT (148 patients) found 28.1% complete wound closure with LL-37 vs. 8.1% placebo in a large-wound subgroup; a smaller RCT in venous leg ulcers also showed improved healing. A Phase I trial tested it via intra-tumoral injection in melanoma, finding acceptable tolerability and variable biological response. Broader immune and antimicrobial mechanisms (disrupting microbial membranes, modulating inflammatory signaling) are well-documented in lab research, while "clinical translation remains in its infancy" for those broader applications.
Sources
Tymalin
Clinical evidence
Decades of real clinical use and striking long-term mortality data in Eastern European research. That evidence comes from clinical practice there and remains to be independently replicated under Western trial standards.
Developed in the 1970s (the same Khavinson/Morozov lab behind Epithalon) and in clinical use for 40+ years in Russia and Eastern Europe, with regulatory approval in those countries. A notable 2021 study found it improved immune status markers and clinical outcomes in elderly COVID-19 patients. Separately, described as "the longest human clinical trial ever conducted on a therapeutic peptide": a 6-year follow-up in elderly patients reportedly found a 45% reduction in cardiovascular mortality and 28% reduction in all-cause mortality. Also used as adjunct therapy for influenza, hepatitis B/C, herpes simplex, and HIV in the countries where it is used clinically. Independent replication under US/EU regulatory review remains to be done.
Sources
PNC-27
An experimental anti-cancer research compound studied in cell cultures. Its evidence base is preclinical, and its research context is oncology rather than immune support.
Framing note: PNC-27 is a p53-derived experimental compound studied for selectively destroying cancer cell membranes in vitro. Its research context is oncology rather than the immune support this area implies. Research to date is cell-culture level (over 20 human cancer cell lines tested) with limited in vivo (animal) data; human clinical trials remain to be run. It holds no approval for human use from any regulatory authority.
Sources
This is a summary of published and preclinical research, not medical advice. Every entry describes what a study found, not what you should do. These compounds are supplied for laboratory research only.
